Login to Your Account



First roxadustat phase III findings set up China filing for Fibrogen

By Marie Powers
News Editor

Monday, January 30, 2017

On the basis of two successful phase III studies in China, Fibrogen Inc. looks headed toward a new drug application submission in the country this year for roxadustat (FG-4592).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription